Patient JourneyFAQsClinical StudiesPost-Procedure InstructionsTestimonialsContact

Umbilical Cord Stem Cell Therapy

The youngest, most potent mesenchymal stem cells available — GMP-expanded Wharton's jelly MSCs for autoimmune, neurological, orthopedic, metabolic, and anti-aging conditions at our Istanbul clinic.

Considering umbilical cord stem cell therapy?

Send your diagnosis and recent labs for a free, written protocol recommendation from our Istanbul medical team within 24 hours.

Request Free ProtocolWhatsApp Us

What Is Umbilical Cord Stem Cell Therapy?

Umbilical cord stem cell therapy uses mesenchymal stem cells (MSCs) isolated from donated full-term umbilical cord tissue — specifically the gelatinous connective tissue known as Wharton's jelly. These cells are the youngest MSCs available outside of embryonic sources, with higher proliferation rates, stronger paracrine signaling, and more consistent characterization than any adult-derived MSC.

At our Istanbul clinic, every cord MSC dose is expanded under cGMP conditions and released only after a full panel of quality checks: ≥90% viability, ISCT surface marker confirmation (CD73, CD90, CD105 positive; CD34, CD45 negative), sterility, endotoxin, and mycoplasma testing. You will be told the exact cell count, viability, and passage number of your dose before infusion.

Treatment is administered as IV infusion for systemic conditions (autoimmune, neurological, anti-aging) or as targeted injection for orthopedic indications. Most patients complete their full treatment in a single 3–5 day visit to Istanbul.

Why Umbilical Cord MSCs?

Compared with bone marrow or adipose-derived stem cells, umbilical-cord-derived MSCs offer measurable advantages in potency, safety, and consistency.

Youngest, most potent MSCs

Umbilical-cord-derived mesenchymal stem cells are the youngest, most proliferative MSCs available — far higher growth and paracrine activity than adult bone-marrow or adipose-derived cells.

Ethically sourced, painless to donor

Cells are isolated from donated full-term umbilical cords after routine, healthy births — no embryonic tissue, no harm to mother or baby, fully consented donations.

GMP-expanded, fully characterized

Every dose is expanded under cGMP conditions and released only after viability ≥90%, ISCT-criteria surface marker confirmation (CD73, CD90, CD105 positive; CD34, CD45 negative), sterility, endotoxin, and mycoplasma testing.

Allogeneic — no harvest from patient

Because umbilical cord MSCs are immune-privileged, donors are not the patient. There's no painful bone-marrow aspiration, no liposuction, no surgical harvest — only a single IV infusion or targeted injection.

Conditions Treated with Umbilical Cord Stem Cells

Osteoarthritis & joint degeneration

Intra-articular injection for knee, hip, shoulder cartilage loss and inflammation.

Autoimmune & inflammatory conditions

Rheumatoid arthritis, lupus, Crohn's, ulcerative colitis, scleroderma — systemic immunomodulation.

Neurological conditions

Multiple sclerosis, post-stroke recovery, ALS, traumatic brain injury, cerebral palsy, autism.

Metabolic & endocrine

Type 1 and type 2 diabetes adjunctive therapy, metabolic syndrome support.

Anti-aging & longevity

Systemic IV protocols for cellular rejuvenation, mitochondrial support, skin and tissue quality.

Sexual wellness & reproductive

Erectile dysfunction, premature ovarian failure, post-menopause vitality support.

Who Is a Good Candidate?

  • Patients with chronic inflammatory, autoimmune, or degenerative conditions seeking a regenerative option beyond symptom management.
  • Patients who do not wish to undergo bone-marrow aspiration or liposuction to harvest their own cells.
  • Children and elderly patients whose own cells would be too immature or senescent for autologous therapy.
  • Patients pursuing anti-aging or longevity protocols who want the most potent allogeneic MSC source available.

Patients with active malignancy, acute infection, pregnancy, or severe immunosuppression require medical assessment before candidacy can be confirmed.

Frequently Asked Questions

Umbilical cord stem cell therapy is a regenerative medicine treatment that uses mesenchymal stem cells (MSCs) isolated from donated, full-term umbilical cord tissue — specifically the Wharton's jelly. These cells are expanded under cGMP conditions and administered to the patient by IV infusion or targeted injection to modulate inflammation, support tissue repair, and release regenerative signaling molecules. It is one of the most studied, safest, and most potent forms of mesenchymal stem cell therapy available today.

Umbilical-cord-derived MSCs are the youngest mesenchymal stem cells available. Compared to bone marrow or adipose stem cells, they have substantially higher proliferative capacity, secrete more anti-inflammatory and regenerative cytokines (paracrine activity), have no donor-site morbidity (no bone marrow aspiration or liposuction), and offer a more consistent, characterized dose because every batch is released under strict cGMP specifications.

Yes. Over 1,200 published clinical studies on umbilical cord MSC therapy document an excellent safety profile across IV, intrathecal, intra-articular, and intranasal routes. Because these cells are immune-privileged, they do not require donor-recipient HLA matching and have no documented graft-versus-host risk. Side effects are uncommon and typically limited to mild transient fatigue or low-grade fever in the 24 hours after infusion.

Yes — completely. Cords are donated by consenting mothers after routine, healthy, full-term births. No embryonic tissue is used. The umbilical cord and placenta would otherwise be discarded as medical waste. Both the mother and the baby are unaffected. Our supply chain is fully traceable from donor consent through GMP processing.

The route depends on the indication. Systemic conditions (autoimmune, neurological, anti-aging) typically use IV infusion. Joint conditions use intra-articular injection under ultrasound guidance. Some neurological protocols add intrathecal (spinal) or intranasal exosome delivery. Most patients receive their full treatment in a single 3–5 day visit to Istanbul.

Single-dose IV umbilical cord MSC therapy at TurkeyStemcell starts at $5,900. Multi-day programs combining IV, intra-articular, and intrathecal routes range from $8,500 to $18,000 depending on condition and dose. Comparable US/EU pricing typically ranges from $25,000 to $80,000 for equivalent protocols.

Most autoimmune, orthopedic, and anti-aging indications respond to a single high-dose course. Chronic neurological conditions (MS, autism, cerebral palsy) typically use a 2–3 session series spaced 3–6 months apart for cumulative effect. We recommend a session plan during consultation based on your specific diagnosis and goals.

Turkey is one of the few countries where mesenchymal stem cell therapy is legally regulated and clinically administered under Ministry of Health oversight. Istanbul offers ISO-accredited cell processing facilities, transparent GMP documentation, English-speaking medical teams, and treatment costs 60–80% below US equivalents — without the regulatory gray areas of other medical-tourism destinations.

Get a Personalized Umbilical Cord MSC Plan

Share your diagnosis and goals — our medical team will design a tailored protocol with documented dose, route, and session count. Free consultation.

Request a Free ConsultationWhatsApp Us

Or call directly: +90 534 856 92 92